Jubilant FoodWorks, Indian Hotels Company and Page Industries from the consumer discretionary space; Ashok Leyland, TVS Motor Company and Bharat Forge from automobiles; AU Small Finance Bank, Muthoot Finance, Shriram Transport Finance Company and Federal Bank from financials; and Adani Transmission, Adani Power and Adani Green Energy from Adani Group were up between 3 per cent and 6 per cent on the BSE.
According to analysts, most of these stocks are surging on anticipation of improved demand that may play out post easing of travel restrictions and pick-up in vaccination drive carried out by the government. The declining daily Covid-19 caseload in the country has also boosted market sentiments.
"As domestic Covid cases fell below the 3 lakh mark for the second day in a row since mid-April, helped by the extended lockdowns by majority states, sentiments have turned buoyant. Hopes have accelerated that soon restrictions/curbs would be eased once cases decline further," said Hemang Jani, Head Equity Strategy, Broking & Distribution at Motilal Oswal Financial Services.
He added: Even the news
flows around vaccination front is boosting confidence as more Pharma companies are tying up for vaccine manufacturing. Visibility on economic recovery front improves as industrial activities largely continued even during the lockdown and now. with restrictions likely to ease, consumer demand is expected to make a come-back. Thus, investors are heading more for mid-cap stocks as growing risk appetite and cheaper valuations of these companies compared to large-cap peers have revived their popularity.
Among other individual stocks from the BSE MidCap
index, Gland Pharma surged 12 per cent to Rs 3,124.75 in the intra-day trade after the company reported a healthy 34 per cent year-on-year (YoY) rise in its consolidated net profit to Rs 260.4 crore in the March 2021 quarter (Q4FY21) on robust sales. It had posted net profit of Rs 194.8 crore in Q4FY20.
The company’s revenue from operations grew 40 per cent YoY at Rs 887.70 crore from Rs 635.2 crore in a year ago quarter. However, earnings before interest, taxes, depreciation, and amortization (EBITDA) margin during the quarter under review declined to 40 per cent from 42 per cent in previous year quarter.
The management said the new product launches, volume growth in company’s existing portfolio, along with geographic expansion, has led to strong business growth across all markets.
The new Vaccine business is expected to accelerate the company’s long-term strategy of entering into Biosimilar space, the management said.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.